IRIS
BODINI, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.722
AS - Asia 65
SA - Sud America 26
NA - Nord America 2
AF - Africa 1
Totale 10.816
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.718
CN - Cina 33
BR - Brasile 18
VN - Vietnam 17
SG - Singapore 6
ID - Indonesia 4
AR - Argentina 3
EC - Ecuador 2
HK - Hong Kong 2
UA - Ucraina 2
US - Stati Uniti d'America 2
VE - Venezuela 2
AZ - Azerbaigian 1
BD - Bangladesh 1
FR - Francia 1
IQ - Iraq 1
PY - Paraguay 1
RU - Federazione Russa 1
ZA - Sudafrica 1
Totale 10.816
Salva come PNG Salva come JPEG
Città #
Genova 5.160
Genoa 3.840
Vado Ligure 928
Rapallo 771
Bordighera 17
Beijing 11
Hanoi 5
Ho Chi Minh City 5
Singapore 5
Ashburn 2
Cachoeira do Sul 2
Guayaquil 2
Hong Kong 2
Hải Dương 2
Thái Bình 2
Baku 1
Barquisimeto 1
Batam 1
Belo Horizonte 1
Betim 1
Biên Hòa 1
Brasília 1
Chacabuco 1
City Bell 1
Ciudad del Este 1
Curitiba 1
Depok 1
Fortaleza 1
Groblersdal 1
Irkutsk 1
Jacobina 1
Kharkiv 1
Lagoa Santa 1
Limeira 1
Nasiriyah 1
Ninh Bình 1
Pirassununga 1
Rio de Janeiro 1
San Miguel de Tucumán 1
Santos 1
São Carlos 1
São Paulo 1
Taboão da Serra 1
Valparaíso de Goiás 1
Xinguara 1
Totale 10.784
Salva come PNG Salva come JPEG
Nome #
Proton pump inhibitors: use and misuse in the clinical setting 185
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 180
Advancements in the use of manometry and impedance testing for esophageal functional disorders 177
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 173
A safety review of proton pump inhibitors to treat acid-related digestive diseases 171
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 167
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 162
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 160
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 157
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 150
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 149
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 147
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 147
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 147
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 146
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 145
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 145
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 142
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 141
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 138
Optimal management of constipation associated with irritable bowel syndrome. 136
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 135
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 133
Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease? 131
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 130
The appropriate use of proton-pump inhibitors 130
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 128
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. 127
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 127
Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients? 126
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 125
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 124
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 123
Prevention of Crohn's disease recurrence after surgery: on the road to recovery. 122
The natural history of gastro-esophageal reflux disease: A comprehensive review 122
Epidemiology and natural history of gastroesophageal reflux disease 122
Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases
 122
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 120
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 116
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 112
Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. 111
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study 111
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 111
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 110
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 110
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 109
Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management 109
Esophageal motility abnormalities in gastroesophageal reflux disease 105
Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels 105
Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease 105
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 104
Gastrointestinal involvement in systemic sclerosis 104
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 103
High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation 103
Esophageal testing: What we have so far 101
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 101
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 100
M01822 Diagnostic accuracy and Inter/Intra-observer Agreement between endoscopists with different expertise, before and after a short training, for the detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 99
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 96
Treatment of early stage chronic hepatitis C virus infection 96
Vegetal and animal food proteins have a different impact in the first postprandial hour of impedance-pH analysis in patients with heartburn 96
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 95
Letter: Biological therapies are effective for prevention of post-operative Crohn's disease recurrence 95
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 95
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 94
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 92
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 90
DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN'S DISEASE BASED ON SERUM LEVELS OF PROTEINS 90
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease 86
The Lyon Consensus: Does it differ from the previous ones? 85
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 84
Vonoprazan fumarate for the management of acid-related diseases 81
Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. 77
Intra- and interobserver Agreement between endoscopists and pathologists for detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 75
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 75
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment 73
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 72
Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I 72
Prospective evaluation on the prevalence of serrated adenoma during a two-year period in an italian endoscopy centre 71
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD 70
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 68
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 66
Esophageal motor disorders across ages: A retrospective multicentric analysis 64
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 64
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 61
Institution of an interdisciplinary IBD centre is associated with improved healthcare utilisation 60
The crohn's disease exclusion diet in adults with mild-to-moderate crohn’s disease activity: A real-world open-label randomized controlled trial 58
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 58
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 56
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 55
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 55
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 54
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 52
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 52
Clopidogrel-Induced Eosinophilic Colitis 50
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand 50
Food Intolerances, Food Allergies and IBS: Lights and Shadows 49
Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice 47
Endoscopic Management of Eosinophilic Esophagitis: A Narrative Review on Diagnosis and Treatment 45
From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease 43
Totale 10.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.436
article - articoli 42.436
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.872
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021735 0 0 0 134 52 66 40 133 65 110 52 83
2021/20221.033 72 34 53 83 35 114 38 238 79 117 51 119
2022/2023963 111 100 14 64 155 118 7 84 166 7 121 16
2023/2024804 28 80 12 106 72 144 64 29 31 35 73 130
2024/20252.427 106 145 116 132 302 269 177 433 104 92 252 299
2025/20261.583 511 211 449 412 0 0 0 0 0 0 0 0
Totale 11.251